drugset / Trial / NCT06614153

Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations

NCT06614153

Phase 2 Completed 61 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverSingle-blindTreatment

Summary

The study is a multicenter, randomized, open-label, active-controlled, Phase II clinical study. The aim of this trial is to evaluated the pharmacokinetics, pharmacodynamics,efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's Disease Patients With Motor Fluctuations.

Timeline

Start
2023-05-16
Primary completion
2024-01-31
Completion
2024-03-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carbidopa Unknown Oral
Subject HRG2010 Unknown Oral
Comparator Levodopa Small molecule Oral

Indications